Business

Gen9 gets $21m boost from Agilent

Agilent Technologies Inc. has made a $21 million investment in Gen9 Inc., a Cambridge company specializing in gene synthesis.

Customers can potentially use Gen9’s technology to more efficiently make everything from fabrics and chemicals to drugs and renewable fuels.

Advertisement

According to Gen9, methods using its technology are more cost-effective than traditional methods.

Headquartered in California, Agilent is a $6.9 billion company focused on chemical analysis, life sciences, ­diagnostics, electronics, and communications.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

In a press release, Agilent said its partnership with Gen9 complements Agilent’s existing investments in synthetic biology and gene synthesis.

Agilent is taking an equity stake in Gen9.

Chris Reidy

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com